Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Global Hodgkin's Lymphoma Market Spotlight 2017-2027 - ResearchAndMarkets.com

Research and Markets
Posted on: 20 Feb 18

The "Market Spotlight: Hodgkin's Lymphoma" report has been added to ResearchAndMarkets.com's offering.

This Market Spotlight report covers the Hodgkin's Lymphoma market, comprising key pipeline and marketed drugs, clinical trials, upcoming and regulatory events, patent information, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways

  • The report estimates that in 2016, there were 70,700 incident cases of Hodgkin's lymphoma worldwide, and expects that number to increase to 77,400 incident cases by 2025.
  • Incidence rates are slightly higher in males compared to females, and are highest in the Northern America region. The approved drugs in the Hodgkin's lymphoma space target DNA, immune system, programmed death-1 receptor/programmed death ligands, antibody-drug conjugate, cluster of differentiation 30/TNFRSF8 and microtubules. The majority of approved drugs are administered via the intravenous route.
  • The majority of industry-sponsored drugs in active clinical development for Hodgkin's lymphoma are in Phase II. Therapies in the pipeline for Hodgkin's lymphoma focus on a wide variety of targets. The majority of the pipeline drugs in development are administered via the oral and intravenous route, with one product being tested in intratumoral formulation.
  • High impact upcoming events for drugs in the Hodgkin's lymphoma space include topline Phase II trial results for AFM13, and estimated PDUFAs for Adcetris and Opdivo.
  • There were eight licensing and asset acquisition activities involving Hodgkin's lymphoma drugs during 2012-17. The largest deal during that time was the $1,410m exclusive licensing agreement (in August 2017) between Dermira, and Roche and Genentech for the development and commercialization of lebrikizumab.
  • Opdivo sales ranked highest in the Hodgkin's lymphoma space during 2012-16 and are forecasted to remain the highest until 2021.
  • The clinical trials distribution across Phase I-IV indicates that the majority of trials for Hodgkin's lymphoma have been in early and mid-phases of development, with 94% of trials in Phase I-II, and only 6% in Phase III-IV.
  • The US has a substantial lead in the number of Hodgkin's lymphoma clinical trials globally. France leads the major EU markets, while China has the top spot in Asia.
  • Clinical trial activity in the Hodgkin's lymphoma space is dominated by completed trials. Takeda, Amgen and Merck & Co. have the highest number of completed clinical trials for Hodgkin's lymphoma, with 42, 28 and 25 completed trials, respectively.
  • Takeda leads industry sponsors with by far the highest number of clinical trials for Hodgkin's lymphoma followed by Merck & Co

Key Topics Covered:

  1. Key Takeaways
  2. Disease Background
  3. Treatment
  4. Epidemiology
  5. Marketed Drugs
  6. Pipeline Drugs
  7. Key Upcoming Events
  8. Key Regulatory Events
  9. Licensing And Asset Acquisition Deals
  10. Parent Patents
  11. Revenue Opportunity
  12. Clinical Trial Landscape
  13. Bibliography
  14. Appendix

For more information about this report visit https://www.researchandmarkets.com/research/9wp5lg/global_hodgkins?w=4

View source version on businesswire.com: http://www.businesswire.com/news/home/20180220006256/en/

Business Wire
www.businesswire.com

Last updated on: 20/02/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.